<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02109484</url>
  </required_header>
  <id_info>
    <org_study_id>VAC-013</org_study_id>
    <nct_id>NCT02109484</nct_id>
    <nct_alias>NCT02132156</nct_alias>
  </id_info>
  <brief_title>Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants</brief_title>
  <official_title>Phase I/II Descending Age Double-blinded Randomized Placebo-controlled Dose Escalation Study to Examine the Safety Reactogenicity Tolerability &amp; Immunogenicity of the P2-VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers &amp; Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is is a study of a parenteral rotavirus vaccine (P2-VP8 subunit rotavirus vaccine). The
      study will examine the safety and immunogenicity of this vaccine first in healthy South
      African toddlers. If the safety profile is deemed appropriate, the study will continue to
      explore the safety and immunogenicity of the vaccine in healthy South African infants.

      The primary safety hypothesis is that the P2-VP8 subunit rotavirus vaccine is safe and
      well-tolerated in healthy toddlers and infants. The primary immunogenicity hypothesis is that
      the P2-VP8 subunit rotavirus vaccine is immunogenic in infant participants and will induce an
      immune response in at least 80% of participants in at least one of the study groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Vaccine Induced Reactions</measure>
    <time_frame>7 days following each dose</time_frame>
    <description>Maximum severity of all local reactions or systemic reactogenicity after any vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>within 28 days of a study dose and at any time</time_frame>
    <description>Number of participants experiencing a Serious Adverse Event within 28 days of a vaccination and at any time during the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Any Non-Serious Adverse Event</measure>
    <time_frame>6 mo following first vaccination</time_frame>
    <description>all adverse events will be recorded over the duration of the 6 month follow up period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percentage of Infant Participants With Anti-P2-VP8 IgA to P[8] Seroresponse.</measure>
    <time_frame>Baseline to day 84</time_frame>
    <description>Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third vaccination). Confidence intervals are displayed as percentages.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percentage of Infants With Anti-P2-VP8 IgG to P[8] Seroresponses</measure>
    <time_frame>Baseline to day 84</time_frame>
    <description>Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/Percentage of Infants With Neutralizing Antibody Response to WA Strain (G1[P8])</measure>
    <time_frame>Baseline to Day 84</time_frame>
    <description>Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rotavirus Shedding After Administration of Rotarix in Infants Receiving 3 Doses of Vaccine or Placebo.</measure>
    <time_frame>Rotarix vaccination on Day 84 to day 91</time_frame>
    <description>Percent of infants who shed rotavirus at any timepoint after receiving 3 doses of study vaccine and one dose of Rotarix. Infants received Rotarix vaccination beginning on Day 84. Stool specimens were collected from these infants on the 5th, 7th and 9th day following first administration of Rotarix. This test was performed as a novel functional assessment of the ability to suppress local gut multiplication of the vaccine strain contained in Rotarix.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Evaluation of a Rotavirus Vaccine</condition>
  <arm_group>
    <arm_group_label>Cohort A P2-VP8 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A toddlers (24-35 mo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A P2-VP8 60 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B P2-VP8 10mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort B infants aged 6 to &lt; 8 weeks receiving placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B P2-VP8 30mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B infants aged 6 to &lt; 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1 P2-VP8 60mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B1 Infants aged 6 to &lt; 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A P2-VP8 10mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P2-VP8 Subunit Vaccine 10mcg</intervention_name>
    <description>10 mcg</description>
    <arm_group_label>Cohort B P2-VP8 10mcg</arm_group_label>
    <arm_group_label>Cohort A P2-VP8 10mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P2-VP8 Subunit Vaccine 30 mcg</intervention_name>
    <description>30 mcg</description>
    <arm_group_label>Cohort A P2-VP8 30 mcg</arm_group_label>
    <arm_group_label>Cohort B P2-VP8 30mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P2-VP8 Subunit Vaccine 60mcg</intervention_name>
    <description>60 mcg</description>
    <arm_group_label>Cohort A P2-VP8 60 mcg</arm_group_label>
    <arm_group_label>Cohort B1 P2-VP8 60mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort A Placebo</arm_group_label>
    <arm_group_label>Cohort B placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy infants/toddlers as established by medical history and clinical examination
             before entering study

          -  age:

               -  toddler cohort: &gt; or = 2 and &lt;3 years old at the time of enrollment

               -  infant cohort: &gt; or = 6 and &lt;8 weeks at the time of enrollment

          -  parental ability and willingness to provide informed consent

          -  parental intention to remain in the area with the child during the study period.

        Exclusion Criteria:

          -  Presence of fever on the day of enrollment

          -  Acute disease at the time of enrollment

          -  Concurrent participation in another clinical trial throughout the entire timeframe for
             this study

          -  Presence of malnutrition or any systemic disorder (cardiovascular, pulmonary, hepatic,
             renal, gastrointestinal, hematological, endocrine, immunological, dermatological,
             neurological, cancer or autoimmune disease) as determined by medical history and/or
             physical examination that would compromise the participant's health or is likely to
             result in nonconformance to the protocol

          -  For infant cohort, history of premature birth (&lt;37 weeks gestation)

          -  History of congenital abdominal disorders, intussusception, or abdominal surgery

          -  Known or suspected impairment of immunological function based on medical history and
             physical examination

          -  For infant cohort only, prior receipt of rotavirus vaccine

          -  A known sensitivity or allergy to any components of the study vaccine

          -  History of anaphylactic reaction

          -  Major congenital or genetic defect

          -  Participant's parents not able, available or willing to accept active weekly follow-up
             by the study staff

          -  Has received any immunoglobulin therapy and/or blood products since birth or planned
             administration during the study period

          -  History of chronic administration (defined as more than 14 days) of immunosuppressant
             medications, including corticosteroids. Infants on inhaled or topical steroids may be
             permitted to participate in the study

          -  Any medical condition in the parents/infant that, in the judgment of the investigator,
             would interfere with or serves as a contraindication to protocol adherence or a
             participant's parents' ability to give informed consent

          -  HIV infection

               -  For toddlers, to be assessed by HIV ELISA

               -  For infants, to be assessed by PCR, if mother is not known to be negative
                  (negative test result between 24 weeks gestation and screening)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Groome</last_name>
    <role>Principal Investigator</role>
    <affiliation>SAMRC Respiratory and Meningeal Pathogen Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Respiratory and Meningeal Pathogens Research Unit (RMPRU)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <results_first_submitted>May 10, 2017</results_first_submitted>
  <results_first_submitted_qc>November 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Age de-escalation, dose-escalation study enrolling healthy toddlers and infants between 17 March and 29 September 2014 at a single site in South Africa.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort A Placebo</title>
          <description>Healthy toddlers aged 2 to &lt;3 months receiving placebo</description>
        </group>
        <group group_id="P2">
          <title>Cohort A 10 mcg P2-VP8</title>
          <description>Healthy toddlers 2 to &lt;3 yrs of age receiving low dose P2-VP8</description>
        </group>
        <group group_id="P3">
          <title>Cohort A 30 mcg P2-VP8</title>
          <description>Healthy toddlers aged 2 to &lt;3 yrs receiving an intermediate dose of P2-VP8</description>
        </group>
        <group group_id="P4">
          <title>Cohort A 60 mcg P2-VP8</title>
          <description>Healthy toddlers aged 2 to &lt; 3 yrs receiving high dose P2-PV8</description>
        </group>
        <group group_id="P5">
          <title>Cohort B Placebo</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving placebo</description>
        </group>
        <group group_id="P6">
          <title>Cohort B 10 mcg P2-VP8</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving low dose P2-VP8</description>
        </group>
        <group group_id="P7">
          <title>Cohort B 30 mcg P2-VP8</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks of age receiving a medium dose of P2-VP8</description>
        </group>
        <group group_id="P8">
          <title>Cohort B 60 mcg P2-VP8</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving high dose of P2-VP8</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="47"/>
                <participants group_id="P8" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved away from study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A Placebo</title>
          <description>Healthy toddlers aged 2 to &lt; 3 years receiving placebo</description>
        </group>
        <group group_id="B2">
          <title>Cohort A 10 mcg P2-VP8</title>
          <description>Healthy toddlers aged 2 to &lt; 3 years receiving low dose P2-VP8</description>
        </group>
        <group group_id="B3">
          <title>Cohort A 30 mcg P2-VP8</title>
          <description>Healthy toddlers aged 2 to &lt; 3 years receiving Medium Dose Ps-VP9</description>
        </group>
        <group group_id="B4">
          <title>Cohort A 60 mcg P2-VP8</title>
          <description>Healthy toddlers aged 2 to &lt; 3 years receiving High Dose P2-VP8</description>
        </group>
        <group group_id="B5">
          <title>Cohort B Placebo</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving placeblo</description>
        </group>
        <group group_id="B6">
          <title>Cohort B 10 mcg P2-VP8</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving Low Dose P2-VP8</description>
        </group>
        <group group_id="B7">
          <title>Cohort B 30 mcg P2-VP8</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving Medium Dose P2-VP8</description>
        </group>
        <group group_id="B8">
          <title>Cohort B 60 mcg P2-VP8</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving High Dose P2-VP8</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="50"/>
            <count group_id="B8" value="50"/>
            <count group_id="B9" value="204"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136.4" lower_limit="126" upper_limit="143"/>
                    <measurement group_id="B2" value="135.6" lower_limit="122" upper_limit="143"/>
                    <measurement group_id="B3" value="139.0" lower_limit="126" upper_limit="152"/>
                    <measurement group_id="B4" value="144.7" lower_limit="139" upper_limit="152"/>
                    <measurement group_id="B5" value="6.6" lower_limit="6.1" upper_limit="7.7"/>
                    <measurement group_id="B6" value="6.6" lower_limit="6.3" upper_limit="7.0"/>
                    <measurement group_id="B7" value="6.6" lower_limit="6.1" upper_limit="7.7"/>
                    <measurement group_id="B8" value="6.7" lower_limit="6.1" upper_limit="8"/>
                    <measurement group_id="B9" value="72.8" lower_limit="6.1" upper_limit="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="49"/>
                    <measurement group_id="B8" value="50"/>
                    <measurement group_id="B9" value="202"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="50"/>
                    <measurement group_id="B8" value="50"/>
                    <measurement group_id="B9" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vaccine Induced Reactions</title>
        <description>Maximum severity of all local reactions or systemic reactogenicity after any vaccination</description>
        <time_frame>7 days following each dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Placebo</title>
            <description>Healthy toddlers aged 2 to &lt;3 months receiving placebo</description>
          </group>
          <group group_id="O2">
            <title>Cohort A 10 mcg P2-VP8</title>
            <description>Healthy toddlers aged 2 to &lt;3 months receiving low dose P2-VP8</description>
          </group>
          <group group_id="O3">
            <title>Cohort A 30 mcg P2-VP8</title>
            <description>Healthy toddlers aged 2 to &lt;3 months receiving Medium Dose P2-VP8</description>
          </group>
          <group group_id="O4">
            <title>Cohort A 60 mcg P2-VP8</title>
            <description>Healthy toddlers aged 2 to &lt;3 months receiving placebo High Dose P2-VP8</description>
          </group>
          <group group_id="O5">
            <title>Cohort B Placebo</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving placebo</description>
          </group>
          <group group_id="O6">
            <title>Cohort B 10 mcg P2-VP8</title>
            <description>Healthy infants aged 6 to &lt; 8 weeks receiving Low Dose P2-VP8</description>
          </group>
          <group group_id="O7">
            <title>Cohort B 30 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Medium Dose P2-VP8</description>
          </group>
          <group group_id="O8">
            <title>Cohort B 60 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving High Dose P2-VP8</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaccine Induced Reactions</title>
          <description>Maximum severity of all local reactions or systemic reactogenicity after any vaccination</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life Threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>Number of participants experiencing a Serious Adverse Event within 28 days of a vaccination and at any time during the study</description>
        <time_frame>within 28 days of a study dose and at any time</time_frame>
        <population>All subjects that received at least one dose of P2-VP8 vaccine or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Placebo</title>
            <description>Healthy toddlers aged 2 to &lt;3 years receiving Placebo</description>
          </group>
          <group group_id="O2">
            <title>Cohort A 10 mcg P2-VP8</title>
            <description>Healthy toddlers aged 2 to &lt;3 years receiving Low Dose P2-VP8</description>
          </group>
          <group group_id="O3">
            <title>Cohort A 30 mcg P2-VP8</title>
            <description>Healthy toddlers aged 2 to &lt;3 years receiving Medium Dose P2-VP8</description>
          </group>
          <group group_id="O4">
            <title>Cohort A 60 mcg P2-VP8</title>
            <description>Healthy toddlers aged 2 to &lt;3 years receiving High Dose P2-VP8</description>
          </group>
          <group group_id="O5">
            <title>Cohort B Placebo</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Placebo</description>
          </group>
          <group group_id="O6">
            <title>Cohort B 10 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Low Dose P2-VP8</description>
          </group>
          <group group_id="O7">
            <title>Cohort B 30 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Medium Dose P2-VP8</description>
          </group>
          <group group_id="O8">
            <title>Cohort B 60 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving High Dose P2-VP8</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>Number of participants experiencing a Serious Adverse Event within 28 days of a vaccination and at any time during the study</description>
          <population>All subjects that received at least one dose of P2-VP8 vaccine or placebo</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE within 28 days of vaccine receipt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE at any time during follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Any Non-Serious Adverse Event</title>
        <description>all adverse events will be recorded over the duration of the 6 month follow up period.</description>
        <time_frame>6 mo following first vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Placebo</title>
            <description>Healthy toddlers aged 2 to &lt;3 months receiving placebo</description>
          </group>
          <group group_id="O2">
            <title>Cohort A 10 mcg P2-VP8</title>
            <description>Healthy toddlers aged 2 to &lt;3 months receiving Low Dose Toddlers P2-VP8</description>
          </group>
          <group group_id="O3">
            <title>Cohort A 30 mcg P2-VP8</title>
            <description>Healthy toddlers aged 2 to &lt;3 months receiving Medium Dose P2-VP8</description>
          </group>
          <group group_id="O4">
            <title>Cohort A 60 mcg P2-VP8</title>
            <description>Healthy toddlers aged 2 to &lt;3 months receiving High Dose P2-VP8</description>
          </group>
          <group group_id="O5">
            <title>Cohort B Placebo</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving placebo</description>
          </group>
          <group group_id="O6">
            <title>Cohort B 10 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Low Dose P2-VP8</description>
          </group>
          <group group_id="O7">
            <title>Cohort B 30 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Medium Dose P2-VP8</description>
          </group>
          <group group_id="O8">
            <title>Cohort B 60 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving High Dose Infants P2-VP8</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Any Non-Serious Adverse Event</title>
          <description>all adverse events will be recorded over the duration of the 6 month follow up period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="46"/>
                    <measurement group_id="O8" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percentage of Infant Participants With Anti-P2-VP8 IgA to P[8] Seroresponse.</title>
        <description>Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third vaccination). Confidence intervals are displayed as percentages.</description>
        <time_frame>Baseline to day 84</time_frame>
        <population>Enrolled infants who received 3 vaccinations and with pre and post-vaccination immunologic parameters measured</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort B Placebo</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving placebo</description>
          </group>
          <group group_id="O2">
            <title>Cohort B 10 mcg P2-VP8</title>
            <description>Healthy infants aged 6 to &lt;8 weeks receiving low dose P2-VP8</description>
          </group>
          <group group_id="O3">
            <title>Cohort B 30 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Medium Dose P2-VP8</description>
          </group>
          <group group_id="O4">
            <title>Cohort B 60 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving High Dose P2-VP8</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Infant Participants With Anti-P2-VP8 IgA to P[8] Seroresponse.</title>
          <description>Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third vaccination). Confidence intervals are displayed as percentages.</description>
          <population>Enrolled infants who received 3 vaccinations and with pre and post-vaccination immunologic parameters measured</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide &gt;= 89% and &gt;= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide &gt; 95% to detect &gt;= 40 percentage point difference between a P2-VP8 dose group and placebo group.</non_inferiority_desc>
            <p_value>0.0165</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide &gt;= 89% and &gt;= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide &gt; 95% to detect &gt;= 40 percentage point difference between a P2-VP8 dose group and placebo group.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide &gt;= 89% and &gt;= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide &gt; 95% to detect &gt;= 40 percentage point difference between a P2-VP8 dose group and placebo group.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide &gt;= 89% and &gt;= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide &gt; 95% to detect &gt;= 40 percentage point difference between a P2-VP8 dose group and placebo group.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percentage of Infants With Anti-P2-VP8 IgG to P[8] Seroresponses</title>
        <description>Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.</description>
        <time_frame>Baseline to day 84</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort B Placebo</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving placebo</description>
          </group>
          <group group_id="O2">
            <title>Cohort B 10 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Low Dose P2-VP8</description>
          </group>
          <group group_id="O3">
            <title>Cohort B 30 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Medium Dose P2-VP8 Medium Dose Infants</description>
          </group>
          <group group_id="O4">
            <title>Cohort B 60 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving High Dose P2-VP8</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Infants With Anti-P2-VP8 IgG to P[8] Seroresponses</title>
          <description>Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unadjusted Seroresponse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted Seroresponse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pair-wise comparisons between Cohort B Placebo group and the active vaccination groups were peformed</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pair-wise comparisons between Cohort B Placebo group and the active vaccination groups were performed</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pair-wise comparisons between Cohort B Placebo group and the active vaccination groups were performed</non_inferiority_desc>
            <p_value>0.0006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number/Percentage of Infants With Neutralizing Antibody Response to WA Strain (G1[P8])</title>
        <description>Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.</description>
        <time_frame>Baseline to Day 84</time_frame>
        <population>Enrolled infants who received placebo, 10 mcg, 30 mcg or 60 mcg V2-VP8.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort B Placebo</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving placebo</description>
          </group>
          <group group_id="O2">
            <title>Cohort B 10 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Low Dose P2-VP8</description>
          </group>
          <group group_id="O3">
            <title>Cohort B 30 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Medium Dose P2-VP8</description>
          </group>
          <group group_id="O4">
            <title>Cohort B 60 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving High Dose P2-VP8</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Infants With Neutralizing Antibody Response to WA Strain (G1[P8])</title>
          <description>Seroresponse is defined as 4 fold rise in Geometric Mean Titer (GMT) between pre-(baseline) and post vaccination (4 weeks after third injection).An unadjusted serioresponse was defined as an increase of 4 times or more in titers between baseline and 4 weeks after the 3rd injection. Adjusted IgG and neutralizing antibody post injection titres accounted for the decay in maternal antibodies using the half-life calculated from participants in the placebo group with detectable baseline titers higher than those at the post injection visit.</description>
          <population>Enrolled infants who received placebo, 10 mcg, 30 mcg or 60 mcg V2-VP8.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unadjusted seroresponse to neutralizing antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted seroresponse to neutralizing antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A pair wise comparison between the Adjusted Seroresponses in the placebo group and the Group B 10 mcg P2-VP8 was performed.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide &gt;= 89% and &gt;= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide &gt; 95% to detect &gt;= 40 percentage point difference between a P2-VP8 dose group and placebo group.</non_inferiority_desc>
            <p_value>0.0004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A pair wise comparison between the Adjusted Seroresponses in the placebo group and the Cohort B 30 mcg P2-VP8 vaccine group was performed.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide &gt;= 89% and &gt;= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide &gt; 95% to detect &gt;= 40 percentage point difference between a P2-VP8 dose group and placebo group.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A pair-wise comparison between the Adjusted Seroresponses in Cohort B Placebo group and the Cohort B P2-VP8 group was performed.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power to detect difference between treatment groups for seroresponse between 50% and 95% for P2-VP8 subunit rotiarivus vaccine calculated based on estimate of 10% loss. 45 evaluable participants in 2 highest doses tolerated in B1 infant cohort, study idesigned to provide &gt;= 89% and &gt;= 77% power to detect 35 and 30 percentage points difference, respectively, between the two dose levels and provide &gt; 95% to detect &gt;= 40 percentage point difference between a P2-VP8 dose group and placebo group.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rotavirus Shedding After Administration of Rotarix in Infants Receiving 3 Doses of Vaccine or Placebo.</title>
        <description>Percent of infants who shed rotavirus at any timepoint after receiving 3 doses of study vaccine and one dose of Rotarix. Infants received Rotarix vaccination beginning on Day 84. Stool specimens were collected from these infants on the 5th, 7th and 9th day following first administration of Rotarix. This test was performed as a novel functional assessment of the ability to suppress local gut multiplication of the vaccine strain contained in Rotarix.</description>
        <time_frame>Rotarix vaccination on Day 84 to day 91</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort B Placebo</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving placebo</description>
          </group>
          <group group_id="O2">
            <title>Cohort B 30 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving Medium Dose P2-VP8</description>
          </group>
          <group group_id="O3">
            <title>Cohort B 60 mcg P2-VP8</title>
            <description>Healthy Infants aged 6 to &lt;8 weeks receiving High Dose P2-VP8</description>
          </group>
        </group_list>
        <measure>
          <title>Rotavirus Shedding After Administration of Rotarix in Infants Receiving 3 Doses of Vaccine or Placebo.</title>
          <description>Percent of infants who shed rotavirus at any timepoint after receiving 3 doses of study vaccine and one dose of Rotarix. Infants received Rotarix vaccination beginning on Day 84. Stool specimens were collected from these infants on the 5th, 7th and 9th day following first administration of Rotarix. This test was performed as a novel functional assessment of the ability to suppress local gut multiplication of the vaccine strain contained in Rotarix.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Timepoint - Rotavirus shedding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No shedding of rotavirus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days after any vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort A Placebo</title>
          <description>Healthy toddlers aged 2 to &lt;3 years receiving Placebo</description>
        </group>
        <group group_id="E2">
          <title>Cohort A 10 mcg P2-VP8</title>
          <description>Healthy toddlers aged 2 to &lt;3 years receiving Low Dose P2-VP8</description>
        </group>
        <group group_id="E3">
          <title>Cohort A 30 mcg P2-VP8</title>
          <description>Healthy toddlers aged 2 to &lt;3 years receiving Medium Dose P2-VP8</description>
        </group>
        <group group_id="E4">
          <title>Cohort A 60 mcg P2-VP8</title>
          <description>Healthy toddlers aged 2 to &lt;3 years receiving High Dose P2-VP8</description>
        </group>
        <group group_id="E5">
          <title>Cohort B Placebo</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving placebo</description>
        </group>
        <group group_id="E6">
          <title>Cohort B 10 mcg P2-VP8</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving Low Dose P2-VP8</description>
        </group>
        <group group_id="E7">
          <title>Cohort B 30 mcg P2-VP8</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving Medium Dose P2-VP8</description>
        </group>
        <group group_id="E8">
          <title>Cohort B 60 mcg P2-VP8</title>
          <description>Healthy Infants aged 6 to &lt;8 weeks receiving High Dose P2-VP8</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>Death unknown cause</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Acute gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Staphylococcal impetigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="46" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="42" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E8" events="8" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Conjuntivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Helminthic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="31" subjects_affected="24" subjects_at_risk="50"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E7" events="31" subjects_affected="25" subjects_at_risk="50"/>
                <counts group_id="E8" events="40" subjects_affected="30" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Viral Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Soft Tissue Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="16" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="15" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitiis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash Papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michelle J. Groome, MD, PhD</name_or_title>
      <organization>Chris Hani Baragwanath Academic Hospital</organization>
      <phone>+27 11 983 4283</phone>
      <email>groomem@rmpru.co.za</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

